Incyte INCY Axatilimab - Commercialization Activities — Accrued and other liabilities
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Incyte’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000879169-26-000056
In connection with the United States co-commercialization efforts, Syndax’s 50% share of profit for the three and six months ended June 30, 2026 was $20.2 million and $34.6 million, respectively, which is reflected in cost of sales on the condensed consolidated statement of operations. At June 30, 2026 and December 31, 2025, $26.5 million and $27.6 million, respectively, was included in accrued and other liability on the consolidated balance sheet for amounts due to Syndax related to United States co-commercialization activities.
Item 1. Financial Statements
FAQ
- What is Incyte's axatilimab - commercialization activities — accrued and other liabilities?
- Incyte (INCY) reported axatilimab - commercialization activities — accrued and other liabilities of $26.5M in Q2 2026.
- What does axatilimab - commercialization activities — accrued and other liabilities mean?
- This metric represents the total outstanding financial obligations and short-term liabilities specifically associated with the commercial launch and market support activities for Axatilimab. It captures deferred costs, accrued marketing expenses, and other operational payables incurred to bring this therapeutic asset to market. Monitoring this balance provides insight into the scale of commercial investment and the timing of cash outflows related to the product's lifecycle.
Ask your AI about Incyte's axatilimab - commercialization activities — accrued and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
